S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
NASDAQ:CDMO

Avid Bioservices - CDMO Stock Forecast, Price & News

$19.69
+0.72 (+3.80%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$18.92
$19.83
50-Day Range
$12.06
$20.36
52-Week Range
$11.30
$34.51
Volume
658,542 shs
Average Volume
621,370 shs
Market Capitalization
$1.22 billion
P/E Ratio
10.64
Dividend Yield
N/A
Price Target
$26.67

Avid Bioservices MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
35.4% Upside
$26.67 Price Target
Short Interest
Bearish
9.46% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.96
Upright™ Environmental Score
News Sentiment
1.24mentions of Avid Bioservices in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$1.30 M Sold Last Quarter
Proj. Earnings Growth
400.00%
From $0.06 to $0.30 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.92 out of 5 stars

Medical Sector

46th out of 1,117 stocks

Pharmaceutical Preparations Industry

14th out of 550 stocks

CDMO stock logo

About Avid Bioservices (NASDAQ:CDMO) Stock

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.

Avid Bioservices Stock Up 0.7 %

NASDAQ:CDMO traded up $0.13 during midday trading on Friday, reaching $19.10. The company had a trading volume of 14 shares, compared to its average volume of 593,637. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of 10.25 and a beta of 2.15. The stock's fifty day simple moving average is $16.54 and its 200-day simple moving average is $17.28. Avid Bioservices has a 12-month low of $11.30 and a 12-month high of $34.51. The company has a current ratio of 2.38, a quick ratio of 2.03 and a debt-to-equity ratio of 0.81.

Avid Bioservices (NASDAQ:CDMO - Get Rating) last announced its quarterly earnings results on Wednesday, June 29th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.02) by $0.06. The company had revenue of $31.23 million during the quarter, compared to the consensus estimate of $29.20 million. Avid Bioservices had a return on equity of 19.70% and a net margin of 106.75%. On average, sell-side analysts anticipate that Avid Bioservices will post 0.06 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Royal Bank of Canada lowered their price target on Avid Bioservices from $32.00 to $22.00 and set an "outperform" rating for the company in a research report on Thursday, June 30th. One equities research analyst has rated the stock with a sell rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $26.67.

Insider Transactions at Avid Bioservices

In other news, CEO Nicholas Stewart Green sold 19,058 shares of Avid Bioservices stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $19.22, for a total transaction of $366,294.76. Following the sale, the chief executive officer now owns 69,708 shares in the company, valued at $1,339,787.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Avid Bioservices news, Director Richard B. Hancock sold 5,000 shares of Avid Bioservices stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $19.40, for a total value of $97,000.00. Following the sale, the director now owns 37,215 shares of the company's stock, valued at approximately $721,971. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Nicholas Stewart Green sold 19,058 shares of Avid Bioservices stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $19.22, for a total value of $366,294.76. Following the completion of the sale, the chief executive officer now directly owns 69,708 shares in the company, valued at approximately $1,339,787.76. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 73,196 shares of company stock worth $1,304,059. Corporate insiders own 1.49% of the company's stock.

Receive CDMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter.

CDMO Stock News Headlines

Is Avid Bioservices (CDMO) a Great Buy?
Avid Bioservices (NASDAQ:CDMO) Shares Gap Up to $17.52
Avid Bioservices (NASDAQ:CDMO) Trading Down 6.6%
Read How Avid Bioservices Fared In Q4
Avid Bioservices's Earnings Outlook
CDMO Avid Bioservices, Inc.
Avid Bioservices's Earnings: A Preview
Avid Bioservices Updates 1 Key Risk Factor
See More Headlines
Receive CDMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter.

CDMO Company Calendar

Last Earnings
6/29/2022
Today
8/12/2022
Next Earnings (Estimated)
9/14/2022
Fiscal Year End
4/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CDMO
Employees
252
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.67
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+35.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$127.67 million
Pretax Margin
10.59%

Debt

Sales & Book Value

Annual Sales
$119.60 million
Cash Flow
$0.37 per share
Book Value
$2.83 per share

Miscellaneous

Free Float
60,914,000
Market Cap
$1.22 billion
Optionable
Optionable
Beta
2.15














CDMO Stock - Frequently Asked Questions

Should I buy or sell Avid Bioservices stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CDMO shares.
View CDMO analyst ratings
or view top-rated stocks.

What is Avid Bioservices' stock price forecast for 2022?

3 brokerages have issued 1 year target prices for Avid Bioservices' stock. Their CDMO share price forecasts range from $22.00 to $30.00. On average, they expect the company's stock price to reach $26.67 in the next year. This suggests a possible upside of 35.6% from the stock's current price.
View analysts price targets for CDMO
or view top-rated stocks among Wall Street analysts.

How have CDMO shares performed in 2022?

Avid Bioservices' stock was trading at $29.18 at the beginning of the year. Since then, CDMO shares have decreased by 32.6% and is now trading at $19.67.
View the best growth stocks for 2022 here
.

When is Avid Bioservices' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, September 14th 2022.
View our CDMO earnings forecast
.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices, Inc. (NASDAQ:CDMO) posted its quarterly earnings data on Wednesday, June, 29th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of ($0.02) by $0.06. The biopharmaceutical company earned $31.23 million during the quarter, compared to the consensus estimate of $29.20 million. Avid Bioservices had a net margin of 106.75% and a trailing twelve-month return on equity of 19.70%.

When did Avid Bioservices' stock split?

Avid Bioservices shares reverse split on the morning of Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What guidance has Avid Bioservices issued on next quarter's earnings?

Avid Bioservices issued an update on its FY 2023 earnings guidance on Wednesday, July, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $140.00 million-$145.00 million, compared to the consensus revenue estimate of $146.50 million.

What is Roger Lias' approval rating as Avid Bioservices' CEO?

5 employees have rated Avid Bioservices Chief Executive Officer Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among the company's employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 63.0% of employees surveyed would recommend working at Avid Bioservices to a friend.

What other stocks do shareholders of Avid Bioservices own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE).

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (9.85%), AltraVue Capital LLC (4.42%), Jennison Associates LLC (3.03%), Geneva Capital Management LLC (2.21%), Artisan Partners Limited Partnership (1.86%) and Redwood Investments LLC (1.43%). Insiders that own company stock include Daniel R Hart, Daniel Ryan Hart, Joseph Carleone, Mark R Bamforth, Mark R Bamforth, Mark R Ziebell, Nicholas Stewart Green, Patrick D Walsh and Richard B Hancock.
View institutional ownership trends
.

How do I buy shares of Avid Bioservices?

Shares of CDMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $19.67.

How much money does Avid Bioservices make?

Avid Bioservices (NASDAQ:CDMO) has a market capitalization of $1.22 billion and generates $119.60 million in revenue each year. The biopharmaceutical company earns $127.67 million in net income (profit) each year or $1.85 on an earnings per share basis.

How many employees does Avid Bioservices have?

The company employs 252 workers across the globe.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The official website for the company is www.avidbio.com. The biopharmaceutical company can be reached via phone at (714) 508-6100, via email at sdiaz@vidasp.com, or via fax at 714-838-5817.

This page (NASDAQ:CDMO) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.